Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Haleon PLC ( (GB:HLN) ) has shared an update.
Haleon PLC announced the notification of share transactions by key managerial personnel, Adrian Morris and Tamara Rogers, involving the acquisition of Partnership Shares and the award of Matching Shares under the company’s Share Reward Plan. This disclosure, in line with UK Market Abuse Regulation, underscores Haleon’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and market perception.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £517.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s overall stock score reflects a strong financial foundation with robust profitability and cash flow, tempered by moderate technical indicators and valuation metrics. The mixed earnings call results, with regional strengths and North American challenges, further influence the score. The company’s strategic focus on innovation and geographic expansion supports a cautiously optimistic outlook.
To see Spark’s full report on GB:HLN stock, click here.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its renowned brands, such as Advil, Centrum, and Sensodyne, are rooted in trusted science and innovation.
Average Trading Volume: 20,655,282
Technical Sentiment Signal: Buy
Current Market Cap: £32.34B
Learn more about HLN stock on TipRanks’ Stock Analysis page.